Chapter 4 of 25
What you will learn
- Distinguish hyperplasia without atypia from EIN or atypical hyperplasia.
- Understand surgery, progestin treatment and repeat sampling.
- Recognize that symptom improvement alone does not prove clearance.
Reading the diagnosis
Hyperplasia without atypia is an increase in glands without the concerning cell changes of atypical disease. Its risk of progression is lower, and many patients can be managed with progestin treatment and surveillance. Endometrial intraepithelial neoplasia, abbreviated EIN, and atypical endometrial hyperplasia describe a precancerous lesion with a higher risk of progression or concurrent cancer. The terminology used may depend on the pathology classification and local practice.
A biopsy samples part of the lining. An EIN diagnosis therefore requires attention to whether cancer was missed elsewhere. Expert pathology review may help if the report is uncertain or fertility-preserving management is being considered. Hysteroscopy with further sampling can assess a focal lesion and improve evaluation for an accompanying carcinoma.
When surgery is recommended
Hysterectomy, removal of the uterus, is the definitive treatment for EIN/atypical hyperplasia in patients who can undergo surgery and do not need to preserve fertility. The operation also allows examination of the entire uterus. Whether ovaries should be removed is a separate discussion based on menopausal status, hereditary risk, possible cancer and long-term health consequences.
Hysterectomy for precancer is not automatically the same operation as staging for confirmed invasive cancer. The surgeon should explain how possible unexpected cancer will be handled. Endometrial ablation, which destroys the lining to reduce bleeding, is not an appropriate substitute for treating EIN because it can leave disease and make future assessment difficult.
Progestin treatment and monitoring
Patients who wish to preserve fertility or cannot safely have surgery may be offered progestin therapy with close surveillance after attempting to exclude invasive cancer. Options include a levonorgestrel-releasing intrauterine system, oral progestins or a combined approach. The specific medicine and regimen require specialist prescribing. A hormonal intrauterine system used for this purpose is an active treatment, not simply contraception.
Repeat histological assessment is essential. ACOG recommends repeat sampling within approximately 3–6 months after starting conservative treatment for EIN/atypical hyperplasia. The team then considers persistence, regression, progression, treatment tolerance and pregnancy goals. A reduction in bleeding or a thinner ultrasound appearance cannot by itself establish complete histological response.
Benefits, limits and adverse effects
Progestins can avoid or delay surgery in selected patients, but require repeated visits and biopsies. Oral treatment may affect appetite, weight, mood and fluid retention; thrombosis risk and other conditions need review. An intrauterine system can cause initial spotting or cramping and occasionally has insertion or placement problems. Discuss how symptoms will be managed rather than stopping treatment silently.
Persistent disease, progression, inability to complete surveillance or recurrence can make surgery the safer option. For patients who respond but are not immediately trying to conceive, maintenance treatment may be considered. After childbearing, definitive surgery should be revisited because response does not eliminate future risk.
Questions, misconceptions and practical steps
| Ask your team | Why it helps |
|---|---|
| Is this without atypia, EIN or invasive cancer? | These diagnoses have different pathways |
| Has concurrent cancer been adequately assessed? | Conservative treatment depends on appropriate selection |
| When is the next biopsy? | Follow-up measures tissue response |
| What finding would lead to surgery? | A clear stopping rule reduces uncertainty |
Precancer is not the same as invasive cancer, but it is not something to ignore. Bring the exact pathology wording to appointments and obtain a written surveillance plan. Lifestyle and metabolic support can accompany treatment; they do not replace it.
Related chapters
- Types of Endometrial Cancer
- Molecular Classification: The Four Major Groups
- How Doctors Choose Treatment
References and review status
- ACOG Clinical Consensus: EIN / atypical hyperplasia, 2023
- RCOG: Management of Endometrial Hyperplasia, Green-top 67
- ESGO/ESHRE/ESGE fertility-sparing guideline, 2023
Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy